Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for chronic prurigo
2021-002818-13Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic prurigo (CPG) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Percent change from baseline in worst itch numerical rating scale at week 12. Started Jan 2023; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic prurigo (CPG)
Beyond the preview
Go deeper on 2021-002818-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002818-13.